New York, USA, March 25, 2024 (GLOBE NEWSWIRE) -- Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The rise in the number of people suffering from cirrhosis can be attributed to rapidly changing lifestyles such as an increase in alcohol consumption and an unbalanced diet.

2024年3月25日，美国纽约（环球通讯社）--肝硬化临床试验管道洞察45家以上公司| DelveInsight肝硬化患者数量的增加可归因于生活方式的快速变化，例如饮酒量的增加和饮食不平衡。

Hence, the rise in the prevalence of the disease is projected to fuel the growth of the global market. DelveInsight’s 'Cirrhosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline cirrhosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the cirrhosis pipeline domain.

因此，预计该疾病流行率的上升将推动全球市场的增长。DelveInsight的“肝硬化管道洞察2024”报告全面覆盖了全球各个临床开发阶段的管道肝硬化治疗，各大制药公司正在努力推进肝硬化管道领域的管道空间和未来增长潜力。

Key Takeaways from the Cirrhosis Pipeline Report DelveInsight’s cirrhosis pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for cirrhosis treatment. Key cirrhosis companies such as GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., Zydus Cadila, Genfit, PRISM Pharma Co, Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., Alentis Therapeutics, Vir Biotechnology, and others are evaluating new cirrhosis drugs to improve the treatment landscape.Promising cirrhosis pipeline therapies such as Belapectin, GXHPC 1, LPCN 1148, Cellgram-LC, Saroglitazar, Elafibranor, OP-724, BMS 986263, CNP-104, HTD 1801, ASC42, ALE.F02, VIR-2218, and others are under different phases of cirrhosis clinical trials.In February 2024, CymaBay Therapeutics announced that the US Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangi.

肝硬化管道报告的关键要点DelveInsight的肝硬化管道报告描述了一个强大的空间，有45多名活跃的参与者致力于开发50多种肝硬化治疗管道疗法。关键的肝硬化公司，如GWOXI Stem Cell Applied Technology，Lipocine，Galectin Therapeutics，Pharmacelle Co.，Ltd.，Zydus Cadila，Genfit，PRISM Pharma Co.，Bristol-Myers Squibb，COUR Pharmaceutical Development Company，Inc.，HighTide Biopharma，Gannex Pharma Co.，Ltd.，Alentis Therapeutics，Vir Biotechnology等正在评估新的肝硬化药物，以改善治疗前景。有前途的肝硬化管道疗法，如Belapectin，GXHPC 1，LPCN 1148，Cellgram LC，Saroglitazar，Elafibranor，OP-724，BMS 986263，CNP-104，HTD 1801，ASC42，ALE。F02，VIR-2218等处于肝硬化临床试验的不同阶段。2024年2月，CymaBay Therapeutics宣布，美国食品和药物管理局（FDA）已接受seladelpar的新药申请（NDA），seladelpar是一种用于治疗原发性胆管结石的研究性治疗方法。